SLC16A14

Summary

SLC16A14 (solute carrier family 16 member 14, HGNC:26417) is a protein-coding gene on chromosome 2q36.3, encoding Monocarboxylate transporter 14 (Q7RTX9). Proton-linked monocarboxylate transporter.

Predicted to enable monocarboxylic acid transmembrane transporter activity. Predicted to be involved in carboxylic acid transmembrane transport. Predicted to be located in membrane. Predicted to be active in plasma membrane.

Source: NCBI Gene 151473 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 37 total
• MANE Select transcript: NM_152527

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26417
Approved symbol	SLC16A14
Name	solute carrier family 16 member 14
Location	2q36.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ30794, MCT14
Ensembl gene	ENSG00000163053
Ensembl biotype	protein_coding
Entrez	151473

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 11 protein_coding

ENST00000295190, ENST00000412034, ENST00000425822, ENST00000436869, ENST00000457406, ENST00000880804, ENST00000880805, ENST00000880806, ENST00000880807, ENST00000880808, ENST00000920474

RefSeq mRNA: 1 — MANE Select: NM_152527 NM_152527

CCDS: CCDS2473

Canonical transcript exons

ENST00000295190 — 5 exons

Exon	Start	End
ENSE00001071163	230034982	230037531
ENSE00001174939	230045745	230046722
ENSE00001343653	230068555	230068924
ENSE00001382609	230049761	230049904
ENSE00001387951	230059094	230059366

Expression profiles

Bgee: expression breadth ubiquitous, 244 present calls, max score 99.04.

FANTOM5 (CAGE): breadth broad, TPM avg 2.4765 / max 56.8238, expressed in 612 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
34443	2.1873	581
34444	0.1276	65
34441	0.0818	36
34442	0.0799	42

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pigmented layer of retina	UBERON:0001782	99.04	gold quality
retina	UBERON:0000966	99.01	gold quality
endothelial cell	CL:0000115	97.33	gold quality
middle temporal gyrus	UBERON:0002771	94.03	gold quality
Brodmann (1909) area 23	UBERON:0013554	93.60	gold quality
cerebellar vermis	UBERON:0004720	91.76	gold quality
parotid gland	UBERON:0001831	89.76	gold quality
skin of hip	UBERON:0001554	89.43	gold quality
Brodmann (1909) area 46	UBERON:0006483	89.37	gold quality
cortical plate	UBERON:0005343	89.16	gold quality
upper leg skin	UBERON:0004262	88.70	gold quality
upper arm skin	UBERON:0004263	88.01	gold quality
lateral nuclear group of thalamus	UBERON:0002736	86.51	gold quality
superior frontal gyrus	UBERON:0002661	86.06	gold quality
pons	UBERON:0000988	85.84	gold quality
primary visual cortex	UBERON:0002436	85.67	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.60	gold quality
visceral pleura	UBERON:0002401	85.51	gold quality
ganglionic eminence	UBERON:0004023	85.13	gold quality
cauda epididymis	UBERON:0004360	84.95	gold quality
postcentral gyrus	UBERON:0002581	84.91	gold quality
occipital lobe	UBERON:0002021	84.86	gold quality
entorhinal cortex	UBERON:0002728	84.67	gold quality
parietal lobe	UBERON:0001872	84.62	gold quality
esophagus squamous epithelium	UBERON:0006920	84.19	gold quality
palpebral conjunctiva	UBERON:0001812	82.56	gold quality
parietal pleura	UBERON:0002400	82.37	gold quality
prefrontal cortex	UBERON:0000451	82.18	gold quality
ventricular zone	UBERON:0003053	81.41	gold quality
frontal cortex	UBERON:0001870	80.94	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-GEOD-135922	yes	13.45
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

116 targeting SLC16A14, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787

Literature-anchored findings (GeneRIF, showing 1)

• Study presented a phylogenetic analysis revealing that Slc16a14 is closely related to Slc16a2, Slc16a9 and Slc16a10; provided a detailed expression analysis of Slc16a14 expression, finding widespread expression in the mouse brain and establishing its expression in neurons and epithelial cells. QRT-PCR on a panel of mouse tissues revealed high Slc16a14 expression in the kidney and moderate levels in the CNS. (PMID:27364523)

Cross-species orthologs

16 orthologs

Organism	Symbol	Gene ID
mus_musculus	Slc16a14	ENSMUSG00000026220
rattus_norvegicus	Slc16a14	ENSRNOG00000017072
drosophila_melanogaster	Mct1	FBGN0023549
drosophila_melanogaster	CG14196	FBGN0031002
drosophila_melanogaster	CG8051	FBGN0031012
drosophila_melanogaster	Sln	FBGN0033657
drosophila_melanogaster	CG8468	FBGN0033913
drosophila_melanogaster	Targ	FBGN0033955
drosophila_melanogaster	CG13907	FBGN0035173
drosophila_melanogaster	out	FBGN0259834
caenorhabditis_elegans		WBGENE00003986
caenorhabditis_elegans		WBGENE00010834
caenorhabditis_elegans		WBGENE00015273
caenorhabditis_elegans		WBGENE00015676
caenorhabditis_elegans		WBGENE00020168
caenorhabditis_elegans		WBGENE00021227

Paralogs (13): SLC16A8 (ENSG00000100156), SLC16A6 (ENSG00000108932), SLC16A10 (ENSG00000112394), SLC16A7 (ENSG00000118596), SLC16A3 (ENSG00000141526), SLC16A2 (ENSG00000147100), SLC16A12 (ENSG00000152779), SLC16A1 (ENSG00000155380), SLC16A9 (ENSG00000165449), SLC16A4 (ENSG00000168679), SLC16A5 (ENSG00000170190), SLC16A11 (ENSG00000174326), SLC16A13 (ENSG00000174327)

Protein

Protein identifiers

Monocarboxylate transporter 14 — Q7RTX9 (reviewed: Q7RTX9)

Alternative names: Solute carrier family 16 member 14

All UniProt accessions (5): C9JIV1, C9JME4, E7EMG7, Q7RTX9, Q6ZWE5

UniProt curated annotations — full annotation on UniProt →

Function. Proton-linked monocarboxylate transporter. May catalyze the transport of monocarboxylates across the plasma membrane.

Subcellular location. Cell membrane.

Similarity. Belongs to the major facilitator superfamily. Monocarboxylate porter (TC 2.A.1.13) family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q7RTX9-1	1	yes
Q7RTX9-2	2

RefSeq proteins (1): NP_689740* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011701	MFS	Family
IPR020846	MFS_dom	Domain
IPR036259	MFS_trans_sf	Homologous_superfamily
IPR050327	Proton-linked_MCT	Family

Pfam: PF07690

UniProt features (19 total): transmembrane region 12, topological domain 2, chain 1, region of interest 1, compositionally biased region 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7RTX9-F1	79.82	0.50

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 109 (showing top): TGGTGCT_MIR29A_MIR29B_MIR29C, NKX25_02, PEREZ_TP63_TARGETS, GOZGIT_ESR1_TARGETS_DN, GOBP_ORGANIC_ACID_TRANSPORT, YAGUE_PRETUMOR_DRUG_RESISTANCE_UP, GOBP_ORGANIC_ANION_TRANSPORT, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN, GOBP_MONOCARBOXYLIC_ACID_TRANSPORT, AACTTT_UNKNOWN, PEREZ_TP53_AND_TP63_TARGETS, JAATINEN_HEMATOPOIETIC_STEM_CELL_UP, TGCCTTA_MIR124A, GOBP_TRANSMEMBRANE_TRANSPORT, NUYTTEN_EZH2_TARGETS_DN

GO Biological Process (3): carboxylic acid transmembrane transport (GO:1905039), monocarboxylic acid transport (GO:0015718), transmembrane transport (GO:0055085)

GO Molecular Function (3): monocarboxylic acid transmembrane transporter activity (GO:0008028), symporter activity (GO:0015293), transmembrane transporter activity (GO:0022857)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
carboxylic acid transport	2
transmembrane transport	2
transport	1
cellular process	1
monocarboxylic acid transport	1
carboxylic acid transmembrane transporter activity	1
secondary active transmembrane transporter activity	1
transporter activity	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

528 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC16A14	ZNF575	Q86XF7	503
SLC16A14	SLC5A12	Q1EHB4	492
SLC16A14	SLC5A8	Q8N695	487
SLC16A14	BSG	P35613	473
SLC16A14	PRELID3B	Q9Y3B1	451
SLC16A14	EMB	Q6PCB8	448
SLC16A14	CYYR1	Q96J86	428
SLC16A14	PDK4	Q16654	406
SLC16A14	BLOC1S6	Q9UL45	404
SLC16A14	CMBL	Q96DG6	401
SLC16A14	IP6K1	Q92551	396
SLC16A14	IRF9	Q00978	388
SLC16A14	JOSD1	Q15040	387
SLC16A14	KCNIP3	Q9Y2W7	387
SLC16A14	HCAR1	Q9BXC0	380

IntAct

3 interactions, top by confidence:

A	B	Type	Score
SLC16A14	GNAQ	psi-mi:“MI:0914”(association)	0.350
SLC16A14	MT-ATP8	psi-mi:“MI:0914”(association)	0.350

BioGRID (12): GNAQ (Affinity Capture-MS), YES1 (Affinity Capture-MS), GNAQ (Affinity Capture-MS), SVIP (Affinity Capture-MS), SLC16A14 (Affinity Capture-RNA), SLC16A14 (Affinity Capture-MS), ANKRD13A (Affinity Capture-MS), APOB (Affinity Capture-MS), BSG (Affinity Capture-MS), CLCC1 (Affinity Capture-MS), ATP8 (Affinity Capture-MS), SPPL3 (Affinity Capture-MS)

ESM2 similar proteins: A0A6I8PMZ8, A1Z7R6, A4IHK6, A4QN56, A7Y2X0, A9JTG4, B1AT66, B2RXV4, F5H094, M0RCI4, O15403, O75387, P34711, P58295, P81721, Q08280, Q08C75, Q0VCM6, Q497L8, Q5BIZ0, Q5R5M4, Q5RCN7, Q5RF58, Q5ZJU0, Q5ZJZ4, Q68EU6, Q6A4L1, Q6PDC8, Q761V0, Q7RTX9, Q7RTY1, Q7SXB7, Q7TM99, Q7TMR7, Q86UG4, Q8BSM7, Q8C0X7, Q8CGA3, Q8K1C7, Q8N370

Diamond homologs: A0LNN5, B1AT66, G5E8K6, O15375, O35308, Q7RTX9, Q7TMR7, Q8K1C7, A1L1W9, G8XYX6, O15374, O70324, P36021, Q3U9N9, Q8K1P8, Q8R0M8, Q8TF71, Q91Y77, A0A2U8U2M7, M0RCI4, O35440, O70451, P53988, Q17QR6, Q5R5M4, Q5ZJU0, Q63344, Q66HE2, Q7RTY0, Q7RTY1, Q7TM99, Q8CE94, A0KGK4, A4SR87, D4A734, O15403, O15427, O35910, O60669, O70461

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

37 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	32
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

952 predictions. Top by Δscore:

Variant	Effect	Δscore
2:230046721:GC:G	acceptor_gain	1.0000
2:230046722:CC:C	acceptor_gain	1.0000
2:230046723:C:CC	acceptor_gain	1.0000
2:230046733:C:CT	acceptor_gain	1.0000
2:230046733:C:T	acceptor_gain	1.0000
2:230046734:G:T	acceptor_gain	1.0000
2:230046736:C:CT	acceptor_gain	1.0000
2:230046737:G:T	acceptor_gain	1.0000
2:230049755:GCTT:G	donor_loss	1.0000
2:230049756:CTTA:C	donor_loss	1.0000
2:230049757:TTA:T	donor_loss	1.0000
2:230049758:TAC:T	donor_loss	1.0000
2:230049759:A:AC	donor_gain	1.0000
2:230049760:C:CC	donor_gain	1.0000
2:230049760:CCAG:C	donor_gain	1.0000
2:230068551:TCA:T	donor_loss	1.0000
2:230068553:ACCG:A	donor_gain	1.0000
2:230068553:ACCGC:A	donor_gain	1.0000
2:230068554:CCG:C	donor_gain	1.0000
2:230068554:CCGC:C	donor_gain	1.0000
2:230068554:CCGCC:C	donor_gain	1.0000
2:230045739:GTTTA:G	donor_loss	0.9900
2:230045741:TTACC:T	donor_loss	0.9900
2:230045742:TA:T	donor_loss	0.9900
2:230045743:A:AG	donor_loss	0.9900
2:230045744:C:CT	donor_loss	0.9900
2:230046718:CAGGC:C	acceptor_gain	0.9900
2:230046719:AGGC:A	acceptor_gain	0.9900
2:230046720:GGC:G	acceptor_gain	0.9900
2:230046725:G:C	acceptor_gain	0.9900

AlphaMissense

3361 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:230045777:C:T	G450D	0.998
2:230045778:C:G	G450R	0.998
2:230046116:A:G	L337P	0.997
2:230046634:G:C	S164R	0.997
2:230046634:G:T	S164R	0.997
2:230046636:T:G	S164R	0.997
2:230046667:G:C	F153L	0.997
2:230046667:G:T	F153L	0.997
2:230046669:A:G	F153L	0.997
2:230059172:A:G	W61R	0.997
2:230059172:A:T	W61R	0.997
2:230045760:C:G	G456R	0.996
2:230045760:C:T	G456R	0.996
2:230045869:A:C	S419R	0.996
2:230045869:A:T	S419R	0.996
2:230045871:T:G	S419R	0.996
2:230045879:C:T	G416E	0.996
2:230049813:A:C	S117R	0.996
2:230049813:A:T	S117R	0.996
2:230049815:T:G	S117R	0.996
2:230045880:C:A	G416W	0.995
2:230045880:C:G	G416R	0.995
2:230045880:C:T	G416R	0.995
2:230046047:G:T	A360E	0.995
2:230046139:G:C	S329R	0.995
2:230046139:G:T	S329R	0.995
2:230046141:T:G	S329R	0.995
2:230046627:C:A	G167W	0.995
2:230059208:C:G	G49R	0.995
2:230046626:C:T	G167E	0.994

dbSNP variants (sampled 300 via entrez): RS1000372846 (2:230064017 A>G), RS1000413305 (2:230050531 A>G), RS1000500895 (2:230062930 C>T), RS1000541602 (2:230053086 T>G), RS1000641746 (2:230045440 A>C), RS1000763038 (2:230050331 C>T), RS1000968280 (2:230065623 A>G), RS1000993337 (2:230068461 TG>T), RS1001036756 (2:230054896 G>A), RS1001148420 (2:230037458 T>A,C), RS1001175390 (2:230062155 T>C), RS1001240908 (2:230058231 A>T), RS1001317680 (2:230052268 A>G), RS1001329027 (2:230052136 C>T), RS1001483707 (2:230044382 G>A)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST005860_3	Cholangiocarcinoma in primary sclerosing cholangitis (time to event)	1.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC16 family of monocarboxylate transporters

CTD chemical–gene interactions

58 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, increases expression	5
Air Pollutants	affects expression, increases abundance, decreases expression	4
Particulate Matter	decreases expression, increases abundance, affects cotreatment, increases expression	4
trichostatin A	decreases expression, increases expression, affects cotreatment	3
sodium arsenite	increases expression, decreases expression, affects cotreatment, increases abundance	3
Ethanol	increases expression, affects cotreatment, decreases expression, increases abundance	3
Tobacco Smoke Pollution	increases expression, decreases expression	3
entinostat	decreases expression, affects cotreatment	2
belinostat	affects cotreatment, decreases expression	2
Panobinostat	affects cotreatment, decreases expression	2
Arsenic	affects methylation, affects cotreatment, increases abundance, increases expression	2
Estradiol	decreases expression, increases expression, affects cotreatment	2
methylmercuric chloride	increases expression	1
bisphenol A	increases expression	1
2,5,2’,5’-tetrachlorobiphenyl	increases expression	1
sulforaphane	increases expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
potassium chromate(VI)	decreases expression	1
cupric chloride	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
NSC 689534	decreases expression, affects binding	1
(+)-JQ1 compound	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Temozolomide	decreases expression	1
Sunitinib	decreases expression	1
Zoledronic Acid	decreases expression	1

Cellosaurus cell lines

7 cell lines: 5 cancer cell line, 2 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4DR	HEK-SLC16A14-KO-c2	Transformed cell line	Female
CVCL_D4DS	HEK-SLC16A14-KO-c6	Transformed cell line	Female
CVCL_D4I3	HCT116-SLC16A14-KO-c4	Cancer cell line	Male
CVCL_D4I4	HCT116-SLC16A14-KO-c5	Cancer cell line	Male
CVCL_D4VA	LS180-SLC16A14-KO-c1	Cancer cell line	Female
CVCL_D4VB	LS180-SLC16A14-KO-c8	Cancer cell line	Female
CVCL_TL66	HAP1 SLC16A14 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.